Abstract
It is currently estimated that roughly 50,000 Americans are affected by some form of muscular dystrophy and many others by the various forms of myopathies. Animal models are critical for our understanding of the numerous muscular diseases that affect people and for the development of targeted gene therapeutics to treat such diseases. Our current understanding of the pathophysiology of these diseases would not be possible without the aid of animal modeling. Multiple animal models have been described, including mice, cats, dogs pigs, etc.; however, the discussion in this chapter will primarily focus on mice and dogs because these two animal models have been more rigorously researched and described. The overall objectives of this chapter are to review the available animal models and their limitations, disease-specific mutations, clinical disease manifestations, and recent advances in associated therapeutic modalities for various muscular disorders, with a focus on dystrophinopathies and limb-girdle muscular dystrophies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Chinwalla A, Cook L, Delehaunty K, Fewell G, Fulton L, Fulton R, Graves T, Hillier L, Mardis E, McPherson J, Miner T, Nash W, Nelson J, Nhan M, Pepin K, Phol C, Ponce T, Schultz B, Thompson J, Travaskis E, Waterston R, Wendl M, Wilson R, Yang S, An P, Berry E, Birren B, Bloom T, Brown D, Butler J, Daly M, David R, Deri J, Dodge S, Foley K, Gage D, Gnerre S, Holzer T, Jaffe D, Kamal M, Karlsson E, Kells C, Kirby A, Kulbokas E, Lander E, Landers T, Leger J, Levine R, Lindblad-Toh K, Mauceli E, Mayer J, McCarthy M, Meldrim J, Mesirov J, Nicol R, Nusbaum C, Seaman S, Sharpe T, Sheridan A, Singer J, Santos R, Spencer B, Stange-Thomann N, Vinson J, Wade C, Wierzbowski J, Wyman D, Zody M, Birney E, Goldman N, Kasprzyk A, Mongin E, Rust A, Slater G, Stabenau A, Ureta-Vidal A, Whelan S, Ainscough R, Attwood J, Bailey J, Barlow K, Beck S, Burton J, Butler J, Campbell R, Carninci P, Cawley S, Chiaromonte F, Chinwalla A, Church D, Clamp M, Clee C, Collins F, Cook L, Copley R, Coulson A, Couronne O, Cuff J, Curwen V, Cutts T, Daly M, David R, Davies J, Delehaunty K, Deri J, Dermitzakis E, Dewey C, Dickens N et al (2002) Initial sequencing and comparative analysis of the mouse genome. Nature 420(6915):520–562. http://www.nature.com/nature/journal/v420/n6915/suppinfo/nature01262_S1.html
Monaco A, Neve R, Colletti-Feener C, Bertelson C, Kurnit D, Kunkel L (1986) Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene. Nature 33:646–650. https://doi.org/10.1038/323646a0
Hoffman E, Brown R, Kunkel L (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51(6):919–928
Spurney C, Knoblach S, Pistilli E, Nagaraju K, Martin G, Hoffman E (2008) Dystrophin-deficient cardiomyopathy in mouse: expression of Nox4 and Lox are associated with fibrosis and altered functional parameter in the heart. Neuromuscul Disord 18(5):371–381
Fine D, Shin J, Yue Y, Volkmann D, Leach S, Smith B, McIntosh M, Duan D (2011) Age-matched comparison reveals early electrocardiography and echocardiography changes in dystrophin-deficient dogs. Neuromuscul Disord 21(7):453–461. https://doi.org/10.1016/j.nmd.2011.03.010
Beggs A (1997) Dystrophinopathy, the expanding phenotype dystrophin abnormalities in X-linked dilated cardiomyopathy. Circulation 95(10):2344–2347
Bouhouch R, Elhouari T, Oukerraj L, Fellat I, Zarzur J, Bennani R, Arharbi M (2008) Management of cardiac involvement in neuromuscular diseases: review. Open Cariovasc Med J 2:93–96. https://doi.org/10.2174/1874192400802010093
Verhaert D, Richards K, Rafael-Fortney J, Raman S (2011) Cardiac involvement in patients with muscular dystrophies: magnetic resonance imaging phenotype and genotypic considerations. Circ Cardiovasc Imaging 4(1):67–76
Carpenter J, Hoffman E, Romanul F, Kunkel L, Rosales R, Ma N, Dasbach J, Rae J, Moore F, McAfee M, Pearce L (1989) Feline muscular dystrophy with dystrophin deficiency. Am J Pathol 135(5):909–919
Klymiuk N, Blutke A, Graf A, Krause S, Burkhardt K, Wuensch A, Krebs S, Kessler B, Zakhartchenko V, Kurome M, Kemter E, Hagashima H, Schoser B, Herbach N, Blum H, Wanke R, Aartsma-Rus A, Thirion C, Lochmuller H, Walter M, Wolf E (2013) Dystrophin-deficient pigs provide new insights into the hierarchy of physiological derangements of dystrophic muscle. Hum Mol Genet 22(21):4368–4382. https://doi.org/10.1093/hmg/ddt287
Collins C, Morgan J (2003) Duchenne’s muscular dystrophy: animal models used to investigate pathogenesis and develop therapeutic strategies. Int J Exp Pathol 84(4):165–172
Sicinski P, Geng Y, Ryder-Cook A, Barnard E, Darlison M, Barnard P (1989) The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 244(4912):1578–1580
Lefaucheur J, Pastoret C, Sebille A (1995) Phenotype of dystrophinopathy in old mdx mice. Anat Rec 242(1):70–76
Sandri M, Podhorska-Okolow M, Geromel V, Rizzi C, Arslan P, Franceschi C, Carraro U (1997) Exercise Induces Myonuclear Ubiquitination and Apoptosis in Dystrophin-deficient Muscle of Mice. J Neuropathol Exp Neurol 56(1):45–57. https://doi.org/10.1097/00005072-199701000–00005
Bostick B, Yue Y, Long C, Duan D (2008) Prevention of dystrophin-deficient cardiomyopathy in twenty-one-month-old carrier mice by mosaic dystrophin expression or complementary dystrophin/utrophin expression. Circ Res 102(1):121–130. https://doi.org/10.1161/CIRCRESAHA.107.162982
Stedman H, Sweeney H, Shrager J, Maquire H, Panettieri R, Petrof B, Narusawa M, Leferovich J, Sladky J, Kelly A (1991) The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature 352(6335):536–539
Metzger T, Gache V, Xu M, Cadot B, Folker E, Richardson B, Gomes E, Baylies M (2012) MAP and kinesin-dependent nuclear positioning is required for skeletal muscle function. Nature 484(7392):120–124
Duddy W, Duguez S, Johnston H, Cohen T, Phadke A, Gordish-Dressman H, Nagaraju K, Gnocchi V, Low S, Partridge T (2016) Muscular dystrophy in the mdx mouse is a severe myopathy compounded by hypotrophy, hypertrophy and hyperplasia. Skelet Muscle 5:16. https://doi.org/10.1186/s13395-015-0041-y
Danko I, Chapman V, Wolff J (1992) The frequency of revertants in mdx mouse genetic models for Duchenne muscular dystrophy. Pediatr Res 32(1):128–131. https://doi.org/10.1203/00006450-199207000-00025
Blake D, Tinsley J, Davies K (1996) Utrophin: a structural and functional comparison to dystrophin. Brain Pathol 6(1):37–47
Deconinck A, Rafael J, Skinner J, Brown S, Potter A, Metzinger L, Watt D, Dickson J, Tinsley J, Davies K (1997) Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 90(4):717–727
Isaac C, Wright A, Usas A, Li H, Tang Y, Mu X, Greco N, Dong Q, Vo N, Kang J, Wang B, Huard J (2013) Dystrophin and utrophin “double knockout” dystrophic mice exhibit a spectrum of degenerative musculoskeletal abnormalities. J Orthop Res 31(3):33–349. https://doi.org/10.1002/jor.22236
Fukada S, Morikawa D, Yamamoto Y, Yoshida T, Sumie N, Yamaguchi M, Ito T, Miyagoe-Suzuki Y, Takeda S, Tsujikawa K, Yamamoto H (2010) Genetic background affects properties of satellite cells and mdx phenotypes. Am J Pathol 176(5):2414–2424. https://doi.org/10.2353/ajpath.2010.090887
Chapman V, Miller D, Armstrong D, Caskey C (1989) Recovery of induced mutations for X chromosome-linked muscular dystrophy in mice. Proc Natl Acad Sci U S A 86(4):1292–1296
Cox G, Phelps S, Chapman V, Chamberlain J (1993) New mdx mutation disrupts expression of muscle and nonmuscle isoforms of dystrophin. Nat Genet 4(1):87–93. https://doi.org/10.1038/ng0593-87
Kohn B, Guscetti F, Waxenberger M, Augsburger H (1993) Muscular dystrophy in a cat. Tierarztl Prax 21(5):451–457
Blunden A, Gower S (2011) Hypertrophic feline muscular dystrophy: diagnostic overview and a novel immunohistochemical diagnostic method using formalin-fixed tissue. Vet Rec 168(19):510. https://doi.org/10.1136/vr.d1119
Gaschen L, Lang J, Lin S, Ade-Damilano M, Busato A, Lombard C, Gaschen F (1999) Cardiomyopathy in dystrophin-deficient hypertrophic feline muscular dystrophy. J Vet Intern Med 13(4):346–356
Sharp N, Kornegay J, Camp SV, Herbstreith M, Secore S, Kettle S, Hung W, Constatinou C, Dykstra M, Roses A, Bartlett R (1992) An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. Genomics 13(1):115–121
Schatzberg S, Olby N, Breen M, Anderson L, Langford C, Dickens H, Wilton S, Zeiss C, Binns M, Kornegay J, Morris G, sharp N (1999) Molecular analysis of a spontaneous dystrophin “knockout” dog. Neuromuscul Disord 9(5):289–295
Winand N, Pradham D, Cooper B (1994) Molecular characterization of severe Duchenne-type muscular dystrophy in a family of Rottweiler dogs. In: Molecular mechanisms of neuromuscular disease. University of Arizona, Tuscon
Smith B, Kornegay J, Duan D (2007) Independent canine models of Duchenne muscular dystrophy due to intronic insertions of repetitive DNA. Mol Ther 15(Supplement 1):S51
Ito D, Kitagawa M, Jeffery N, Okada M, Yoshida M, Kobayashi M, Nakamura A, Watari T (2011) Dystrophin-deficient muscular dystrophy in an Alaskan malamute. Vet Rec 169(5):127. https://doi.org/10.1136/vr.d2693
Shrader SM, Jung S, Denney TS, Smith BF (2018) Characterization of Australian Labradoodle dystrophinopathy. Neuromuscular Disord 28(11):927–937. https://doi.org/10.1016/j.nmd.2018.08.008
Wieczorek L, Garosi L, Shelton G (2006) Dystrophin-deficient muscular dystrophy in an old English sheepdog. Vet Rec 158:270–273
Beltran E, Shelton G, Guo L, Dennis R, Sanchez-Masian D, Robinson D, Risio LD (2015) Dystrophin-deficient muscular dystrophy in a Norfolk terrier. J Small Anim Pract 56(5):351–354. https://doi.org/10.1111/jsap.12292
Kornegay J, Bogan J, Bogan D, Childers M, Li J, Nghiem P, Detwiler D, Larsen C, Grange R, Bhavaraju-Sanka R, Tou S, Keene B, Howard J, Wang J, Fan Z, Schatzberg S, Styner M, Flanigan K, Xiao X, Hoffman E (2012) Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies. Mamm Genome 23(1-2):85–108. https://doi.org/10.1007/s00335-011-9382-y
Atencia-Fernandez S, Shiel R, Mooney C, Nolan C (2015) Muscular dystrophy in the Japanese Spitz: an inversion disrupts the DMD and RPGR genes. Anim Genet 46(2):175–184. https://doi.org/10.1111/age.1226
Jones B, Brennan S, Mooney C, Callahan J, McAllister H, Guo L, Martin P, Engvall E, Shelton G (2004) Muscular dystrophy with truncated dystrophin in a family of Japanese Spitz dogs. J Neurol Sci 217(2):143–149
Walmsley G, Arechavala-Gomeza V, Fernandez-Fuente M, Burke M, Nagel N, Holder A, Stanley R, Chandler K, marks S, Muntoni F, Shelton G, Piercy R (2010) A Duchenne muscular dystrophy gene hot spot mutation in dystrophin-deficient Cavalier King Charles spaniels is amenable to exon 51 skipping. PLoS One 5(1):e8647. https://doi.org/10.1371/journal.pone.0008647
Valentine B, Cooper B, de Lahunta A, O’Quinn R, Blue J (1988) Canine X-linked muscular dystrophy. An animal model of Duchenne muscular dystrophy: clinical studies. J Neurol Sci 88(1-3):69–81
Shimatsu Y, Katagiri K, Furuta T, Nakura M, Tanioka Y, Yuasa K, Tomohiro M, Kornegay J, Nonaka I, Takeda S (2003) Canine X-linked muscular dystrophy in Japan (CXMDJ). Exp Anim 52(2):93–97
Smith B, Yue Y, Woods P, Kornegay J, Shin J, Williams R, Duan D (2011) An intronic LINE-1 element insertion in the dystrophin gene aborts dystrophin expression and results in Duchenne-like muscular dystrophy in the Corgi breed. Lab Investig 91(2):216–231
Schatzberg S, Anderson L, Wilton S, Kornegay J, Mann C, Solomon G, Sharp N (1998) Alternative dystrophin gene transcripts in golden retriever muscular dystrophy. Muscle Nerve 21(8):991–998
Howell J, Lochmuller H, O’Hara A, Fletcher S, Kakulas B, Massie B, Nalbantoglu J, Karpati G (1998) High-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscle of dystrophic dogs: prolongation of expression with immunosuppression. Hum Gene Ther 9(5):629–634. https://doi.org/10.1089/hum.1998.9.5-629
Nakagaki K, Gebhard D, Bogan D, Kornegay J (1994) Selection of canine myogenic cells with panning. Muscle Nerve 17(Supplement 1):S260
Nakagaki K, Gebhard D, Bogan D, Kornegay J (1994) A quantitative comparison of NCAM-positive muscle cells from normal and dystrophic dogs. Muscle Nerve 17(Supplement 1):S193
Tremblay J, Malouin F, Roy R, Huard J, Bouchard J, Satoh A, Richards C (1993) Results of a triple blind clinical study of myoblast transplantations without immunosuppressive treatment in young boys with Duchenne muscular dystrophy. Cell Transplant 2(2):99–112
Miller R, Sharma K, Pavlath G, Gussoni E, Mynhier M, Lanctot A, Greco C, Steinman L, Blau H (1997) Myoblast transplantation in Duchenne muscular dystrophy: The San Francisco Study. Muscle Nerve 20(4):469–478
Gussoni E, Blau H, Kunkel L (1997) The fate of individual myoblasts after transplantation into muscles of DMD patients. Nat Med 3:970–977. https://doi.org/10.1038/nm0997-970
Townsend D, Turner I, Yasuda S, Martindale J, Davis J, Shillingford M, Kornegay J, Metzger J (2010) Chronic administration of membrane sealant prevents severe cardiac injury and ventricular dilatation in dystrophic dogs. J Clin Invest 120(4):1140–1150
Mahmood O, Jiang X (2014) Limb-girdle muscular dystrophies: where next after six decades from the first proposal. Mol Med Rep 9(5):1515–1532. https://doi.org/10.3892/mmr.2014.2048
Olive M, Goldfarb L, Shatunov A, Fischer D, Ferrer I (2005) Myotilinopathy: refining the clinical and myopathological phenotype. Brain 128(Part 10):2315–2326
Gilchrist J, Pericak-Vance M, Silverman L, Roses A (1988) Clinical and genetic investigation in autosomal dominant limb-girdle muscular dystrophy. Neurology 38(1):5–9
Shalaby S, Misuhashi H, Matsuda C, Minami N, Noguchi S, Nonaka I, Nishino I, Hayashi Y (2009) Defective myotilin homodimerization caused by a novel mutation in MYOT exon 9 in the first Japanese limb girdle muscular dystrophy 1A patient. J Neuropathol Exp Neurol 68(6):701–707
Reilich P, Krause S, Schramm N, Klutzny U, Bulst S, Zehetmayer B, Schneiderat P, Walter MC, Schoser B, Lochmuller H (2011) A novel mutation in the myotilin gene (MYOT) causes a severe form of limb girdle muscular dystrophy 1A (LGMD1A). J Neurol 258(8):1437–1444
Hauser M, Conde C, Kowaljow V, Zeppa G, Taratuto A, Torian U, Vance J, Pericak-Vance M, Speer M, Rosa A (2002) Myotilin Mutation found in second pedigree with LGMD1A. Am J Hum Genet 71(6):1428–1432. https://doi.org/10.1086/344532
Hauser M, Horrigan S, Salmikangas P, Torian U, Viles K, Dancel R, Tim R, Taivainen A, Bartoloni L, Gilchrist J, Stajich J, Gaskell P, Gilbert J, Vance J, Pericak-Vance M, Carpen O, Westbrook C, Speer M (2000) Myotilin is mutated in limb girdle muscular dystrophy 1A. Hum Mol Genet 9(14):2141–2147
Garvey S, Miller S, Claflin D, Faulkner J, Hauser M (2006) Transgenic mice expressing the myotilin T57I mutation unite the pathology associated with LGMD1A and MFM. Hum Mol Genet 15(15):2348–2362
Garvey S, Liu Y, Miller S, Hauser M (2008) Myotilin overexpression enhances myopathology in the LGMD1A mouse model. Muscle Nerve 37(5):663–667. https://doi.org/10.1002/mus.20994
Liu J, Wallace L, Garwick-Coppens S, Sloboda D, Davis C, Hakim C, Hauser M, Brooks S, Mendell J, Harper S (2014) RNAi-mediated $$ in LGMD1A Mi$$ce. Mol Ther Nucleic Acids 3:e160. https://doi.org/10.1038/mtna.2014.13
Bonne G, Barletta MD, Varnous S, Becane H, Hammouda E, Merlini L, Mutoni F, Greenberg C, Gary F, Uritizberea J, Duboc D, Fardeau M, Toniolo D, Schwartz K (1999) Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat Genet 21(3):285–288. https://doi.org/10.1038/6799
Muchir A, Bonne G, Avd K, Mv M, Baas F, Bolhuis P, Md V, Schwartz K (2000) Identification of mutations in the gene encoding lamins A/C in autosomal dominant limb girdle muscular dystrophy with atrioventricular conduction disturbances (LGMD1B). Hum Mol Genet 9(9):1453–1459
Fatkin D, MacRae C, Sasaki T, Wolff M, Porcu M, Frenneaux M, Atherton J, Vidaillet H, Spudich S, Girolami UD, Seidman J, Seidman C, Mutoni F, Muehle G, Johnson W, McDonough B (1999) Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med 341(23):1715–1724
Sullivan T, Escalante-Alcalde D, Bhatt H, Anver M, Bhat N, Nagashima N, Stewart C, Burke B (1999) Loss of A-type lamin expression compromises nuclear envelope integrity leading to muscular dystrophy. J Cell Biol 147(5):913–920
Stewart C, Kozlov S, Fong L, Young S (2007) Mouse models of the laminopathies. Exp Cell Res 313(10):2144–2156
Kubben N, Voncken J, Konings G, van Weeghel M, van den Hoogenhof M, Gijbels M, van Erk A, Schoonderwoerd K, van den Bosch B, Dahlmans V, Calis C, Houten S, Misteli T, Pinto Y (2011) Post-natal myogenic and adipogenic developmental: defects and metabolic impairment upon loss of A-type lamins. Nucleus 2(3):195–207. https://doi.org/10.4161/nucl.2.3.15731
Angelini C (2014) Limb-girdle muscular dystrophy type 1C. In: Genetic neuromuscular disorders: a case-based approach. Springer International Publishing, Cham. https://doi.org/10.1007/978-3-319-07500-6
Sunada Y, Ohi H, Hase A, Ohi H, Hosono T, Arata S, Higuchi S, Matsumura K, Shimizu T (2001) Transgenic mice expressing mutant caveolin-3 show severe my-opathy associated with increased nNOS activity. Hum Mol Genet 10(3):173–178
Woodman S, Park D, Cohen A, Cheung M, Chandra M, Shirani J, Tang B, Jelicks L, Kitsis R, Christ G, Factor S, Tanowitz H, Lisanti M (2002) Caveolin-3 knock-out mice develop a progressive cardiomyopathy and show hyperactivation of the p42/44 MAPK cascade. J Biol Chem 277(41):38988–38997
Galbiati F, Engelman J, Volonte D, Zhang X, Minetti C, Li M, Hou H, Kneitz B, Edelmann W, Lisanti M (2001) Caveolin-3 Null Mice Show a Loss of Caveolae, Changesin the Microdomain Distribution of the Dystrophin-Glycoprotein Complex, and T-tubule Abnormalities. J Biol Chem 276(24):21425–21433. https://doi.org/10.1074/jbc.M100828200
Kramerova I, Beckmann J, Spencer M (2007) Molecular and cellular basis of calpainopathy (limb girdle muscular dystrophy type 2A). Biochim Biophys Acta 1772(2):128–144. https://doi.org/10.1016/j.bbadis.2006.07.002
Kramerova I, Kudryashova E, Venkatraman G, Spencer M (2005) Calpain 3 participates in muscle remodeling by acting upstream of the ubiquitin-proteasome pathway. Hum Mol Genet 14(15):2125–2134. https://doi.org/10.1093/hmg/ddi217
Kramerova I, Kudryashova E, Tidball J, Spencer M (2004) Null mutation of calpain 3 (p94) in mice causes abnormal sarcomere formation in vivo and in vitro. Hum Mol Genet 13(13):1378–1388. https://doi.org/10.1093/hmg/ddh153
Fougerousse F, Gonin P, Durand M, Richard I, Raymackers J (2003) Force impairment in calpain 3-deficient mice is not correlated with mechanical disruption. Muscle Nerve 27(5):616–623. https://doi.org/10.1002/mus.10368
Ho M, Post CM, Donahue LR, Lidov HGW, Bronson RT, Goolsby H, Watkins SC, Cox GA, Brown RH (2004) Disruption of muscle membrane and phenotype divergence in two novel mouse models of dysferlin deficiency. Hum Mol Genet 13(18):1999–2010. https://doi.org/10.1093/hmg/ddh212
Kobayashi K, Izawa T, Kuwamura M, Yamate J (2010) The distribution and characterization of skeletal muscle lesions in dysferlin-deficient SJL and A/J mice. Exp Toxicol Pathol 62(5):509–517. https://doi.org/10.1016/j.etp.2009.06.009
Kobayashi K, Izawa T, Kuwamura M, Yamate J (2012) Dysferlin and Animal Models for Dysferlinopathy. J Toxicol Pathol 25(2):135–147. https://doi.org/10.1293/tox.25.135
Duclos F, Straub V, Moore S, Venzke D, Hrstka R, Crosbie R, Durbeej M, Lebakken C, Ettinger A, van der Meulen J, Holt K, Lim L, Sanes J, Davidson B, Faulkner J, Wililamson R, Campbell K (1998) Progressive muscular dystrophy in α-sarcoglycan-deficient mice. J Cell Biol 142(6):1461–1471. https://doi.org/10.1083/jcb.142.6.1461
Fanin M, Melacini P, Boito C, Pegoraro E, Angelini C (2003) LGMD2E patients risk developing dilated cardiomyopathy. Neuromuscul Disord 13(4):303–309
Pozsgai E, Griffin D, Heller K, Mendell J, Rodino-Klapac L (2016) β-Sarcoglycan gene transfer decreases fibrosis and restores force in LGMD2E mice. Gene Ther 23(1):57–66
Lopate G (2016) Limb-girdle muscular dystrophy. Medscape. http://emedicine.medscape.com/article/1170911-overview. Accessed Jan 2 2017
Bushby K (2012) Limb-girdle muscular dystrophies. National Organization for Rare Disorders. https://rarediseases.org/rare-diseases/limb-girdle-muscular-dystrophies/. Accessed 10 Jan 2017
Hack A, Lam M, Cordier L, Shoturma D, Ly C, Hadhazy M, Hadhazy M, Sweeney H, McNally E (2000) Differential requirement for individual sarcoglycans and dystrophin in the assembly and function of the dystrophin-glycoprotein complex. J Cell Sci 113(Pt 2):2532–2544
Nigro V, Moreira ES, Piluso G, Vainzof M, Belsito A, Politano L, Puca A, Passos-Bueno M, Zatz M (1996) Autosomal recessive limbgirdle muscular dystrophy, LGMD2F, is caused by a mutation in the δ-sarcoglycan gene. Nat Genet 14(2):195–198
Duggan D, Manchester D, Stears K, Mathews D, Hart C, Hoffman E (1997) Mutations in the delta-sarcoglycan gene are a rare cause of autosomal recessive limb-girdle muscular dystrophy (LGMD2). Neurogenetics 1(1):49–58
Homburger F, Baker J, Nixon C, Whitney R (1962) Primary, generalized polymyopathy and cardiac necrosis in an inbred line of Syrian hamsters. Med Express 6(5):339–345. https://doi.org/10.1159/000135178
Holt K, Lim L, Straub V, Venzke D, Duclos F, Anderson R, Davidson B, Campbell K (1998) Functional rescue of the sarcoglycan complex in the BIO 14.6 hamster using delta-sarcoglycan gene transfer. Mol Cell 1(6):841–848
Toyo-Oka T, Kawada T, Nakata J, Xie H, Urabe M, Masui F, Ebisawa T, Tezuka A, Iwasawa K, Nakajima T, Uehara Y, Kumagai H, Kostin S, Schaper J, Nakazawa M, Ozawa K (2004) Translocation and cleavage of myocardial dystrophin as a common pathway to advanced heart failure: a scheme for the progression of cardiac dysfunction. Proc Natl Acad Sci U S A 101(19):7381–7385
Mitsuhashi S, Saito N, Watano K, Igarashi K, Tagami S, Shima H, Kikuchi K (2003) Defect of δ-sarcoglycan gene is responsible for development of dilated cardiomyopathy of a novel hamster strain, J2N-k: calcineurin/PP2B activity in the heart of J2N-k hamster. J Biochem 132(2):269–276
Hunter E, Hughes V, White J (1984) Cardiomyopathic hamsters, CHF 146 and CHF 147: a preliminary study. Can J Physiol Pharmacol 62(11):1423–1428
Coral-Vazquez R, Cohn R, Moore S, Hill J, Weiss R, Davisson R, Straub V, Barresi R, Bansal D, Hrstka R, Williamson R, Campbell K (1999) Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: a novel mechanism for cardiomyopathy and muscular dystrophy. Cell 98(4):465–474
Nomura T, Ashihara E, Tateishi K, Asada S, Ueyama T, Takahashi T, Matsubara H, Oh H (2007) Skeletal myosphere-derived progenitor cell transplantation promotes neovascularization in δ-sarcoglycan knockdown cardiomyopathy. Biochem Biophys Res Commun 352(3):668–374
Shelton G, Engvall E (2005) Canine and feline models of human inherited muscle diseases. Neuromuscul Disord 15(2):127–138
Schatzberg S (2003) Sarcoglycanopathy in 3 dogs. In: Proceedings of the American College of Veterinary Internal Medicine. American College of Veterinary Internal Medicine, Dallas
Saccone V, Palmieri M, Passamano L, Piluso G, Meroni G, Politano L, Nigro V (2008) Mutations that impair interaction properties of TRIM32 associated with limb-girdle muscular dystrophy 2H. Hum Mutat 29(2):240–247
Frosk P, Greenberg C, Tennese A, Lamont R, Nylen E, Hirst C, Frappier D, Roslin N, Zaik M, Bushby K, Straub V, Zatz M, de Paula F, Morgan K, Fujiwara T, Wrogemann K (2005) The most common mutation in FKRP causing limb girdle muscular dystrophy type 2I (LGMD2I) may have occurred only once and is present in Hutterites and other populations. Hum Mutat 25(1):38–44. https://doi.org/10.1002/humu.20110
Beltran-Valero de Bernabé D, Voit T, Longman C, Steinbrecher A, Straub V, Yuva Y, Herrmann R, Sperner J, Korenke C, Diesen C, Doboyns W, Brunner H, van Bokhoven H, Brockington M, Muntoni F (2004) Mutations in the FKRP gene can cause muscle-eye-brain disease and Walker-Warburg syndrome. J Med Genet 41(5):e61
Boito C, Melacini P, Vianello A, Prandini P, Gavassini B, Bagattin A, Siciliano G, Angelini C, Pegoraro E (2005) Clinical and molecular characterization of patients with limb-girdle muscular dystrophy type 2I. Arch Neurol 62(12):1894–1899. https://doi.org/10.1001/archneur.62.12.1894
Ackroyd M, Skordis L, Kluarachchi M, Godwin J, Prior S, Fidanboylu M, Piercy R, Mutoni F, Brown S (2009) Reduced expression of fukutin related protein in mice results in a model for fukutin related protein associated muscular dystrophies. Brain 132:439–451. https://doi.org/10.1093/brain/awn335
Wang C, Chan Y, Tang R, Xiao B, Lu P, Keramaris-Vrantsis E, Zheng H, Qiao C, Jiang J, Li J, Ma H, Lu Q, Xiao X (2011) Post-natal knockdown of fukutin-related protein expression in muscle by long-term RNA interference induces dystrophic pathology. Am J Pathol 178(1):261–272. https://doi.org/10.1016/j.ajpath.2010.11.020
Blaeser A, Keramaris E, Chan Y, Sparks S, Cowley D, Xiao X, Lu Q (2013) Mouse models of fukutin-related protein mutations show a wide range of disease phenotypes. Hum Genet 132(8):923–934. https://doi.org/10.1007/s00439-013-1302-7
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Shrader, S.M., Wrighten, R., Smith, B.F. (2019). Animal Models for Muscle Disease and Muscle Gene Therapy. In: Duan, D., Mendell, J. (eds) Muscle Gene Therapy. Springer, Cham. https://doi.org/10.1007/978-3-030-03095-7_3
Download citation
DOI: https://doi.org/10.1007/978-3-030-03095-7_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-03094-0
Online ISBN: 978-3-030-03095-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)